A Trial of Aerosolized Colistin for the Treatment of Nosocomial Pneumonia due to Multidrug-resistant Acinetobacter baumannii.
10.4046/trd.2008.64.2.102
- Author:
Changhwan KIM
1
;
Dong Gyu KIM
;
Hye Ryun KANG
;
Jeong Hee CHOI
;
Chang Youl LEE
;
Yong Il HWANG
;
Tae Rim SHIN
;
Sang Myeon PARK
;
Yong Bum PARK
;
Jae Young LEE
;
Seung Hun JANG
;
Cheol Hong KIM
;
Eun Kyung MO
;
Myung Goo LEE
;
In Gyu HYUN
;
Ki Suck JUNG
;
Young Jin CHOI
;
Jae Woong LEE
Author Information
1. Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea. dongyu@hallym.ac.kr
- Publication Type:Controlled Clinical Trial ; Original Article
- Keywords:
Acinetobacter baumannii;
Aerosolized colistin;
Nosocomial pneumonia
- MeSH:
Acinetobacter;
Acinetobacter baumannii;
Albuterol;
Bronchial Spasm;
Colistin;
Cystic Fibrosis;
Follow-Up Studies;
Humans;
Intensive Care Units;
Length of Stay;
Medical Records;
Pneumonia;
Retrospective Studies
- From:Tuberculosis and Respiratory Diseases
2008;64(2):102-108
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Recently, multidrug-resistant (MDR) A. baumannii has been implicated for a significant proportion of nosocominal pneumonia in many intensive care units (ICUs), and its acquisition may increase mortality and the length of stay in the ICU. Aerosolized colistin has been successfully used in patients with cystic fibrosis, but there is a lack of data regarding the use of aerosolized colistin in patients with nosocomial pneumonia. METHODS: We conducted the present study to assess the effectiveness of aerosolized colistin for the treatment of MDR A. baumannii nosocomial pneumonia. We retrospectively reviewed the medical records of 10 patients who had been hospitalized in the medical ICU and had received aerosolized colistin as a therapy for MDR A. baumannii pneumonia. RESULTS: The mean duration of aerosolized colistin therapy was 12.7+/-2.4 days. Nine (90%) of 10 patients showed a favorable response to the therapy. Follow-up cultures were available for all patients, and the responsible pathogen was completely eradicated. One patient suffered from bronchospasm, which resolved after treatment with nebulized salbutamol. CONCLUSION: Our results corroborate previous reports that aerosolized colistin may be an effective and safe choice for the treatment of nosocomial pneumonia caused by MDR A. baumannii. Larger prospective controlled clinical studies are warranted to validate further the effectiveness and safety of aerosolized colistin therapy.
